MAPT and Alzheimer disease: Due to conflicting study results in the literature, we tested the ability of the AD CSF core biomarkers Aβ1–42, p-tau, t-tau, and the p-tau/Aβ1–42 ratio, measured at baseline, to predict shunt responsiveness in iNPH patients.